Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks
J Eur Acad Dermatol Venereol
.
2022 Dec;36(12):e1021-e1023.
doi: 10.1111/jdv.18427.
Epub 2022 Jul 26.
Authors
L Mastorino
1
,
V L Cantafio Duò
1
,
C Vecco
1
,
F Gelato
1
,
S Giordano
1
,
G Roccuzzo
1
,
G Cavaliere
1
,
G Avallone
1
,
M Ortoncelli
1
,
S Ribero
1
,
P Quaglino
1
Affiliation
1
Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
PMID:
35841298
DOI:
10.1111/jdv.18427
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized* / therapeutic use
Dermatitis, Atopic* / drug therapy
Double-Blind Method
Humans
Severity of Illness Index
Treatment Outcome
Substances
dupilumab
Antibodies, Monoclonal, Humanized